Neuro Bo Pharmaceuticals
Pharmaceuticals, 177 Huntington Ave, Boston, Massachusetts, 02116, United States, 1-10 Employees
Phone Number: 85********
Who is NEUROBO PHARMACEUTICALS
NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimers disease. Our Phase III-ready drug, NB-01, is based on natural sources and has shown s...
Read More
- Headquarters: 177 Huntington Ave, Boston, Massachusetts, 02116, United States
- Date Founded: 2017
- Employees: 1-10
- Revenue: $5 Million to $10 Million
- Active Tech Stack: See technologies
- CEO: Hyung Kim
Industry: Pharmaceuticals
SIC Code: 2836 | NAICS Code: 541714 | Show More
Does something look wrong? Fix it. | View contact records from NEUROBO PHARMACEUTICALS
NeuroBo Pharmaceuticals Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding NeuroBo Pharmaceuticals
Answer: NeuroBo Pharmaceuticals's headquarters are located at 177 Huntington Ave, Boston, Massachusetts, 02116, United States
Answer: NeuroBo Pharmaceuticals's phone number is 85********
Answer: NeuroBo Pharmaceuticals's official website is https://neurobopharma.com
Answer: NeuroBo Pharmaceuticals's revenue is $5 Million to $10 Million
Answer: NeuroBo Pharmaceuticals's SIC: 2836
Answer: NeuroBo Pharmaceuticals's NAICS: 541714
Answer: NeuroBo Pharmaceuticals has 1-10 employees
Answer: NeuroBo Pharmaceuticals is in Pharmaceuticals
Answer: NeuroBo Pharmaceuticals contact info: Phone number: 85******** Website: https://neurobopharma.com
Answer: NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimers disease. Our Phase III-ready drug, NB-01, is based on natural sources and has shown successful Phase II results with excellent efficacy and safety in diabetic neuropathic pain (DNP) and we have strong preclinical data in both neuropathic pain and diabetes models showing a mode of action of NB-01 on nerve growth factor (NGF) release for nerve stabilization and regeneration. 40 to 50 percent of patients with diabetic peripheral neuropathy have some form of neuropathic pain and while existing drugs alleviate pain symptoms, they do not address the underlying disease. These current therapies also have a range of adverse effects, and only about 50 percent of patients respond positively. Additionally, the current therapies on the market were all initially approved for other disease states such as depression and fibromyalgia. NB-02, our lead Alzheimers drug, is in IND-enabling stage and has been extensively characterized in rodent models for mechanisms impacting Alzheimers disease (inhibition of AChE, pTau, amyloid-, and stimulation of NGF for nerve growth. An aging population has resulted in an increase in the prevalence of Alzheimers disease, and the disease is a significant healthcare burden. Today, there are four approved drugs that manage the symptoms of Alzheimers disease, yet none of these four address disease modification.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month